Labiotech.eu

News and Trends 10 Mar 2017

Galapagos finds a Partner to Boost its Pipeline with Drug Combinations

Galapagos and Pharnext will work together to develop low-dose drug combinations that improve drug efficacy and target new indications. Galapagos, the biggest biotech in Belgium, has closed an R&D agreement with the French Pharnext to develop drug combinations of the billion-euro biotech’s drug candidates with already approved drugs. While Pharnext’s focus has been neurodegenerative diseases, the […]

March 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Mar 2017

SynBio Success with Enzyme opens Jet Fuel Production Possibilities

The well-known but stubborn FAS enzyme has been successfully modified to make petrol and jet fuel. This research opens up possibilities to produce biofuels with engineered microorganisms, or “cell factories”. Researchers from Chalmers University of Technology in Sweden have developed a method to modify the enzyme fatty acid synthase (FAS). This complex enzyme has long been […]

March 10, 2017 - 2 minutesmins - By Denise Neves Gameiro

Research Integrin beta 3 cellular senescence

More News! 9 Mar 2017

There’s a New Target for Anti-Aging Therapies

According to a study at Queen Mary University of London (QMUL) published in the journal Cell Reports, the protein integrin-ß3 is a new marker and regulator of cellular senescence. Past research has revealed that the rising number of senescent cells, which appear during normal ageing, contributes to many age-related diseases. In a new study by Ana O’Loghlen and collegues, integrin-ß3 has been identified as […]

March 9, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 9 Mar 2017

Even if you don’t like IP, here’s Why Biotech Should Care about It

Biotech is renowned for its huge profits; but these would be nonexistent without intellectual property. What is the role of IP law in the industry? There is yet no other industry sector in which IP plays such an important role as in biotech, life sciences and pharma. The development of a new drug is a costly matter […]

March 9, 2017 - 4 minutesmins - By External Contributor

Best in Biotech 8 Mar 2017

Which European Blockbusters Topped the Charts in 2016?

Blockbuster drugs are raking in billions each year in sales. Let’s have a look at the top 7 European best-seller drugs of 2016 and what their competition has to say. Not surprisingly, the top 3 best-selling drugs in Europe are biologicals, which are revolutionizing the treatment possibilities for a range of conditions, from cancer to chronic diseases. But with the increasing […]

March 8, 2017 - 4 minutesmins - By Melanie De Almeida

breath therapeutics sofinnova fundraising

News and Trends 8 Mar 2017

German Biotech closes Largest Series A Fundraising of 2017 So Far

Breath Therapeutics has raised €43.5M that will be used to finalize development and launch a therapy to improve survival in lung transplant patients. Sofinnova Partners, one of the top biotech VCs in Europe, and the Belgian Gimv have co-led the Series A round of Breath Therapeutics, a German company focusing on treating pulmonary orphan indications. […]

March 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 8 Mar 2017

International Women’s Day: An Infographic on Gender Diversity in Biotech

Today we celebrate women and promote a more gender-inclusive industry. Biotech is infamous for its divide, but what are the numbers? Whether it’s launching the next generation of insulin or running the business arm of one of Europe’s leading immuno-oncology biotechs, women have made major strides in biotechnology as some prominent leaders on the scene. “I […]

March 8, 2017 - 3 minutesmins - By Evelyn Warner

More News! 7 Mar 2017

UPDATE: Reproductive Health Biotech starts Phase III after €90M IPO

UPDATE (07/03/2017): ObsEva has announced the start of its Phase III trials for nolasiban, an oral oxytocin receptor antagonist. It is under evaluation for improvements in pregnancy and live birth rates following embryo transfer (ET). UPDATE (26/01/2017): ObsEva has disclosed plans to release 6.45M shares at $15 (€14) each, for a total of €90.3M. This large total reflects […]

March 7, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Mar 2017

A New Transatlantic Partnership takes on Antibiotic Resistance

The Swiss biotech BioVersys and the US company Aptuit have entered a new collaboration to target antibiotic resistances. BioVersys, based in Basel, is developing small molecules that interfere with bacterial resistance mechanisms. Its current research is focused on nosocomial infections (hospital infections) and tuberculosis. To advance the development of compounds against novel targets identified by BioVersys, the company has […]

March 7, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 6 Mar 2017

The ‘Underdog of the UK?’ 8 Companies Proving the Welsh Biotech Scene

How is biotech in Wales? We take a look at some companies based in the ‘Land of Song,’ their plans and their achievements. After taking a look at the vibrant biotech clusters in the UK like London and Cambridge and picking the top biotechs in Scotland, it’s time to direct our attention to the western part […]

March 6, 2017 - 4 minutesmins - By External Contributor

Interview 6 Mar 2017

How did this Biotech seal a €1B Deal with AstraZeneca? The CEO Explains

We talked to the CEO of Bicycle Therapeutics, Kevin Lee, about how his company’s technology could cure not just cancer but also a raft of other diseases. Bicycle Therapeutics made a splashy debut in 2014 with a €25M fundraising round, only to outdo it with a €1B deal with AstraZeneca last fall. What’s the fuss? […]

March 6, 2017 - 7 minutesmins - By Evelyn Warner

News and Trends 4 Mar 2017

Meet the Finnish Bioartist using Yeast to Create Vanishing Photographs

Johanna Rotko creates living art with yeast to explore the perishableness of matter and how we interact with nature around us. Johanna Rotko is a visual artist and photographer based in Kotka, Finland, that decided to explore alternative photographic methods. The result were yeastograms, living images made with yeast on petri dishes that disappear over […]

March 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Galapagos finds a Partner to Boost its Pipeline with Drug Combinations

SynBio Success with Enzyme opens Jet Fuel Production Possibilities

There’s a New Target for Anti-Aging Therapies

Even if you don’t like IP, here’s Why Biotech Should Care about It

Which European Blockbusters Topped the Charts in 2016?

German Biotech closes Largest Series A Fundraising of 2017 So Far

International Women’s Day: An Infographic on Gender Diversity in Biotech

UPDATE: Reproductive Health Biotech starts Phase III after €90M IPO

A New Transatlantic Partnership takes on Antibiotic Resistance

The ‘Underdog of the UK?’ 8 Companies Proving the Welsh Biotech Scene

How did this Biotech seal a €1B Deal with AstraZeneca? The CEO Explains

Meet the Finnish Bioartist using Yeast to Create Vanishing Photographs

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!